Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
MerusN. V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1.
The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors.
In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | -1.40 Decreased by -137.29% | -1.06 Decreased by -31.63% |
| Feb 26, 25 | -0.49 Increased by +52.88% | -0.90 Increased by +45.69% |
| Oct 31, 24 | -1.46 Decreased by -239.53% | -0.88 Decreased by -65.91% |
| Aug 1, 24 | -0.81 Decreased by -22.73% | -0.76 Decreased by -6.58% |
| May 8, 24 | -0.59 Increased by +31.40% | -0.81 Increased by +27.16% |
| Feb 28, 24 | -1.04 Increased by +42.54% | -0.74 Decreased by -40.54% |
| Nov 2, 23 | -0.43 Increased by +18.87% | -0.73 Increased by +41.10% |
| Aug 7, 23 | -0.66 Decreased by -407.69% | -0.88 Increased by +25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 9.14 M Increased by +15.86% | -30.92 M Increased by +10.25% | Decreased by -338.33% Increased by +22.54% |
| Dec 31, 24 | 9.14 M Increased by +2.25% | -30.92 M Increased by +48.59% | Decreased by -338.33% Increased by +49.72% |
| Sep 30, 24 | 11.77 M Increased by +6.70% | -99.91 M Decreased by -334.14% | Decreased by -848.67% Decreased by -306.89% |
| Jun 30, 24 | 7.33 M Decreased by -30.01% | -50.04 M Decreased by -56.22% | Decreased by -682.52% Decreased by -123.21% |
| Mar 31, 24 | 7.89 M Decreased by -41.56% | -34.46 M Increased by +13.30% | Decreased by -436.76% Decreased by -48.36% |
| Dec 31, 23 | 8.94 M Decreased by -16.19% | -60.15 M Increased by +26.62% | Decreased by -672.93% Increased by +12.44% |
| Sep 30, 23 | 11.03 M Increased by +67.65% | -23.01 M Increased by +6.51% | Decreased by -208.57% Increased by +44.24% |
| Jun 30, 23 | 10.48 M Decreased by -17.41% | -32.03 M Decreased by -460.61% | Decreased by -305.78% Decreased by -578.76% |